Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders

Posttransplant lymphoproliferative disorders.

Posttransplant lymphoproliferative disorder is a heterogeneous group of clonal hyperplasia/neoplasms that can range from benign to highly malignant lesions. Mortality rates can approach 60%. This entity has been on the rise for the last 2 decades with the advent of highly potent immunosuppressive agents. Epstein-Barr virus has shown to play a primary role in more than 90% of the cases. Although...

Posttransplant Lymphoproliferative Disorders

Posttransplant lymphoproliferative disorders (PTLDs) are a group of diseases that range from benign polyclonal to malignant monoclonal lymphoid proliferations. They arise secondary to treatment with immunosuppressive drugs given to prevent transplant rejection. Three main pathologic subsets/stages of evolution are recognised: early, polymorphic, and monomorphic lesions. The pathogenesis of PTLD...

Posttransplant Lymphoproliferative Disorders

Classification and Treatment of Posttransplant Lymphoproliferative Disorders

ABSTR ACT: Posttransplant lymphoproliferative disorders (PTLDs) are defined by the 2008 World Health Organization classification. Monomorphic PTLD is the most frequent form; it is usually diagnosed several years after transplantation and nowadays is positive for Epstein–Barr virus in only 50% of cases. Although preventive treatments are not effective, in cases of Epstein–Barr virus reactivation...

Thoracic presentations of posttransplant lymphoproliferative disorders.

BACKGROUND Posttransplant lymphoproliferative disorders (PTLDs) are rare complications following transplantation. Although organ-specific cases have been reported, primary presentation in the thoracic cavity has not been fully characterized. METHODS Eleven cases of PTLD with a primary thoracic presentation were identified among 3,085 solid-organ transplant patients and 1,662 bone marrow trans...